Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 10/20 | 0.70 |
| ▸ | ICAM1 | P05362 | 10/20 | 0.70 |
| ▸ | ITGAL | P20701 | 10/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143425 | 0.83 | ITGAL (0.74) | ITGB2ICAM1ITGAL | |
| SCHEMBL7144872 | 0.79 | ITGB2 (0.44) | ITGB2ICAM1ITGALHPGDSIGMAR1 | |
| SCHEMBL7170387 | 0.69 | ITGB2 (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL6069145 | 0.66 | ITGB2 (0.48) | ITGB2ICAM1ITGALMAPT | |
| SCHEMBL6956020 | 0.65 | ITGB2 (0.53) | ITGB2ICAM1ITGALTSHR | |
| SCHEMBL7135305 | 0.65 | ITGB2 (0.60) | ITGB2ICAM1ITGALSIGMAR1MAPT | |
| SCHEMBL7170389 | 0.64 | ITGB2 (0.75) | ITGB2ICAM1ITGALSIGMAR1 | |
| SCHEMBL19701952 | 0.64 | HPGD (0.57) | HPGDSIGMAR1 | |
| SCHEMBL6194900 | 0.64 | ITGB2 (0.49) | ITGB2ICAM1ITGAL | |
| SCHEMBL6194902 | 0.63 | ITGB2 (0.62) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | claimed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | claimed |
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICAM1, VCAM1, CD47 | ITGB2 120/4885ICAM1 1/4885ITGAL 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.